Ownership and insider activity for Beam Therapeutics Inc. (BEAM): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia.
Price
| Price | $27.23 (closing price, October 30, 2026) |
| Market Cap | $2.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-16 | Evans John M. | M-Exempt | 25,000 | $26K |
| 2026-10-15 | Evans John M. | S-Sale | 25,000 | $589K |
| 2026-10-16 | Evans John M. | S-Sale | 25,000 | $600K |
| 2026-10-15 | Evans John M. | M-Exempt | 25,000 | $26K |
| 2026-10-16 | Evans John M. | M-Exempt | 25,000 | $26K |
| 2026-10-01 | Cavanagh Bethany J | S-Sale | 187 | $5K |
| 2026-09-24 | Ciaramella Giuseppe | G-Gift | 123,407 | |
| 2026-07-27 | Simon Amy | S-Sale | 16,667 | $429K |
| 2026-06-30 | Simon Amy | S-Sale | 373 | $13K |
| 2026-06-30 | Evans John M. | M-Exempt | 25,000 | $26K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.9M | $146.4M | $37.2M | $162.2M | $560.0M | $232.8M | $435.9M | $282.0M | $294.9M |
| Short-term Investments | 0 | 0 | $54.6M | $137.5M | $405.7M | $845.4M | $754.0M | $568.8M | $950.3M |
| Receivables | 0 | 0 | 0 | 0 | $300.0M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.0M | $148.3M | $94.5M | $308.3M | $1.27B | $1.09B | $1.21B | $878.1M | $1.27B |
| Property, Plant & Equipment | $335,000 | $16.9M | $43.2M | $125.4M | $187.0M | $234.1M | $237.8M | $216.3M | $205.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $2.4M | $167.0M | $156.1M | $451.7M | $1.47B | $1.34B | $1.46B | $1.10B | $1.48B |
| Accounts Payable | $726,000 | $7.4M | $7.8M | $6.3M | $7.5M | $9.0M | $1.6M | $3.9M | $10.2M |
| Short-term Debt | $1.0M | 0 | $1.3M | $2.1M | $2.3M | 0 | 0 | 0 | $14.4M |
| Total Current Liabilities | $6.6M | $25.6M | $29.1M | $102.3M | $213.4M | $223.6M | $205.6M | $182.1M | $96.9M |
| Long-term Debt | 0 | 0 | $4.4M | $5.3M | $3.0M | 0 | 0 | 0 | $139.8M |
| Total Liabilities | $6.6M | $33.0M | $55.2M | $206.1M | $647.7M | $608.2M | $478.4M | $370.3M | $242.8M |
| Retained Earnings | -$9.5M | -$124.7M | -$203.0M | -$397.6M | -$768.3M | -$1.06B | -$1.19B | -$1.57B | -$1.64B |
| Total Equity | -$4.2M | $134.0M | $100.9M | $245.6M | $826.7M | $733.5M | $981.3M | $733.5M | $1.24B |
| Total Debt | $1.0M | 0 | $31.2M | $107.6M | $147.6M | $179.0M | $172.7M | $161.4M | $293.9M |
| Net Debt | -$891,000 | -$146.4M | -$60.6M | -$192.0M | -$818.0M | -$899.1M | -$1.02B | -$689.3M | -$951.3M |
| Working Capital | -$4.5M | $122.7M | $65.4M | $206.0M | $1.06B | $869.3M | $1.01B | $696.1M | $1.17B |
Financial Health
| Debt / Equity | 0.23 |
| Current Ratio | 14.57 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 5.41 |
Profitability
| Return on Equity | -7.70% |
| Return on Invested Capital | -28.62% |
| Return on Assets | -6.16% |
| Gross Margin | 100.00% |
| Operating Margin | -242.27% |
| Net Margin | -54.75% |
Related companies: CRSP · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of BEAM: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks